Erythropoiesis Stimulation and Heart Failure: Current Status
|
|
- Benedict Gregory
- 5 years ago
- Views:
Transcription
1 Erythropoiesis Stimulation and Heart Failure: Current Status Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital Boston, Massachusetts Disclosures: Dr. Pfeffer receives research grants, or serves as a consultant for Amgen, Astra Zeneca, Baxter, Biogen, Boehringer, Boston Scientific, Bristol-Myers Squibb, Celladon, Centocor, CVRx, Genentech, Genzyme, Medtronic, Novartis, Roche, Sanofi Aventis, Via and Zensun. Dr. Pfeffer is a co-inventor of a patent awarded to BWH regarding the use of inhibitors of the renin-angiotensin system in selected survivors of MI. A licensing agreement with Boehringer Ingelheim and Novartis is not linked to sales.
2 Possible etiologies of anemia in heart failure Bone marrow - Insensitivity to EPO - Cytokines (TNF ) Malnutrition - Low iron - Vitamine B11,B12 Renal failure - EPO production Anemia Chronic blood loss - Use of Anticoagulation Medication - Use of ACE-inhibitors Hemodilution Van der Meer et al, Eur Heart J. 2004
3 CHARM CV death or HF hospitalization and Anemia O'Meara, E. et al. Circulation 2006;113:
4 O'Meara, E. et al. Circulation 2006;113: CHARM All cause mortality per Haemoglobin Quintiles % 35 Hgb Hgb 12.8 Hgb 13.6 Hgb Hgb I II III IV V Haemoglobin quintiles
5 Kaplan-Meier survival curve by Hb strata (all-cause mortality) COMET-study Komajda, Poole-Wilson, et al. Eur Heart J :
6 Anemia and Mortality in Heart Failure Patients A Systematic Review and Meta-Analysis Hessel F. Groenveld, MD,* James L. Januzzi, MD, FACC, Kevin Damman, MD,* Jan van Wijngaarden, MD, PHD, Hans L. Hillege, MD, PHD,* Dirk J. van Veldhuisen, MD, PHD, FACC,* Peter van der Meer, MD, PHD J Am Coll Cardiol 2008;52: Risk of All-Cause Mortality of Anemic Versus Nonanemic CHF Patients: n = Conclusions: Anemia is associated with an increased risk of mortality in both systolic and diastolic CHF. Anemia should, therefore, be considered as a useful prognosticator, and therapeutic strategies aimed to increase hemoglobin levels in CHF should be investigated.
7 Use of Erythropoietin in Heart Failure First data in 26 patients, treated for 7.2 months Silverberg et al. JACC 2000
8 Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) 1432 Patients Randomized 715 Group A (Hb 13.5 g/dl) 717 Group B (Hb 11.3 g/dl) 279 Early Withdrawal without experiencing primary endpoint 271 Early Withdrawal without experiencing primary endpoint DSMB Stopped Study May 2005 for Futility (not a stopping rule) Results Released April 2006 at NKF meeting Singh A et al. NEJM 2006
9 Achieved 12.6 g/dl Achieved 11.3 g/dl 17.5% vs. 13.5%; HR 1.34; 95% CI ; P = 0.03 NEJM 2006;355:
10 Kaplan-Meier Failure Estimate (%) Kaplan-Meier Failure Estimate (%) CHOIR Components of 1 Endpoint 20% 15% 10% p = Death Hazard ratio (0.969, 2.268) CHF 20% Hospitalization (where RRT did not occur) 15% 10% p = Hazard ratio (0.967, 2.054) 5% H = 52 L = 36 0% % H = 64 L = 47 0% % 15% 10% 5% Stroke 20% 15% p = p = Hazard ratio (0.454, 2.249) H = 12 L = 12 10% 5% Myocardial Infarction Hazard ratio (0.484, 1.729) H = 18 L = 20 0% Months from Randomization 0% Months from Randomization Randomized Treatment Hemoglobin Target 13.5 g/dl Hemoglobin Target 11.3 g/dl Singh A et al. NEJM 2006
11 Singh A et al. NEJM 2006
12 Hemoglobin (g/dl) Pooled Efficacy Results Hemoglobin Response Hemoglobin Concentrations (Mean SE) Over Time* N=209 N=263 N=201 N=254 N=199 N=256 N=198 N=257 N=201 N=255 N=195 N=252 N=194 N=253 N=187 N=238 N=184 N=240 N=179 N=237 N=179 N=245 N=178 N=236 N=176 N=231 N=175 N=229 N=127 N=140 BL Visit Week Darbepoetin alfa *For subjects in study 170 who stayed on study longer than 27 weeks, the Hb concentration remained stable throughout the study Placebo
13 Pooled Safety Results Summary Placebo n = 209 Darbepoetin alfa n = 264 Any adverse events, n (%) 184 (88) 231 (88) Serious adverse events, n (%) 94 (45) 101 (38) Deaths, n (%) 18 (9) 17 (6) Study 170 deaths* 18 (11) 11 (7) Study 171 deaths* 0 (0) 6 (6) Number of subjects with adverse events of special interest**, n (%) 67 (32) 69 (26) Hypertension 12 (6) 15 (6) Deep vein thrombosis 2 (1) 0 (0) Pulmonary emboli 1 (<1) 0 (0) Heart failure 53 (25) 50 (19) Cerebrovascular disorder 4 (2) 9 (3) Myocardial infarction 5 (2) 6 (2) Seizure 2 (1) 1 (<1) *n for placebo vs. darbepoetin alfa in studies 170 and 171 were 157 and 162, and 55 and 108, respectively **No anti-erythropoietic protein neutralizing antibodies were detected
14 Erythropoietin Treatment in HF: meta-analysis P Van der Meer et al. Heart 2009; 95:
15 Erythropoietin Treatment in HF: meta-analysis Effect on all-cause mortality P Van der Meer et al. Heart 2009; 95:
16 Erythropoietin Treatment in HF: meta-analysis Effect on HF Hospitalizations P Van der Meer et al. Heart 2009; 95:
17 HF and Anemia studies as of 08/25/ Anemia AND HF 22 studies Therapeutic intervention 15 Observational, Case-control 7 Iron Supplementation 7 PRBC post MI M/M endpoint 92 patients Erythropoietin Stimulating Agents 7 6 RCTs, 1 open label VO 2, ΔHgb, QOL 3165 patients Non M/M ΔHgb, VO2, QOL, remodeling 580 patients (largest 300) Mortality/Morbidity 1 RCT 2600 patients
18 European Journal of Heart Failure (2009) 11,
19 RED-HF Trial 2600 patients planned primary endpoint: morbidity and mortality target: 620 sites, 32 countries first patients in: July 2006 August 2010: ~ 2/3 of target enrolled
20 Trial to Reduce Cardiovascular Events with Aranesp Therapy Marc A. Pfeffer, Emmanuel A. Burdmann, Chao-Yin Chen, Mark E. Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Jan M. Feyzi, Peter Ivanovich, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, John J.V. McMurray, Patrick Parfrey, Hans-Henrik Parving, Giuseppe Remuzzi, Ajay K. Singh, Scott D. Solomon, Robert Toto for the TREAT investigators* Disclosures: This study was sponsored by Amgen. All investigators received research funding and some received consulting fees from the sponsor. A full list of disclosures is publicly released.
21 Survival Probability (All-Cause Mortality) Incremental Risk of CKD and Anaemia on Mortality in Subjects With Diabetes 1.0 ARIC, Cardiovascular Health Study, Framingham Heart Studies. n = 3015 subjects with DM DM DM, Anaemia DM, CKD Hypothesis Anemia+, CKD+, (71) HR: 2.84 (2.05 to 3.91) Anemia+, CKD-, (174) HR: 1.21 (0.89 to 1.65) Anemia-, CKD+, (344) HR: 1.51 (1.25 to 1.82) Anemia-, CKD-, (2426) HR: 1 In patients with type 2 diabetes, chronic kidney disease not requiring dialysis, and concomitant anaemia, raising haemoglobin with darbepoetin alfa would lower the rates of death and cardiovascular morbidity and/or death and end-stage renal disease Years Since Baseline Vlagopoulos PT et al. J Am Soc Nephrol 16: , 2005 DM, CKD, Anaemia
22 Design International (24) multi-center (623), doubleblind, placebo-controlled randomized trial Randomization in a 1:1 Active: darbepoetin alfa to attempt to achieve and maintain a hemoglobin (Hb) of 13 g/dl Control: placebo: with rescue therapy if Hb <9.0 g/dl with resumption of placebo once Hb 9.0 g/dl Blinding maintained during computer directed adjustments assigning pre-filled syringes
23 Endpoints 2 composite primary endpoints* Cardiovascular composite: death, MI, myocardial ischemia, CHF, stroke. alpha Renal composite: death or ESRD. alpha *All endpoints centrally adjudicated committee unaware of treatment assignment and with hemoglobin and hematocrit values masked from source documents
24 Baseline Characteristics Variable % Darbepoetin alfa N = 2012 Placebo N = 2026 P-value Age (years) Women CVD history CAD Heart failure Myocardial infarction Stroke PAD Systolic BP mmhg Diastolic BP mmhg egfr ml/min/1.73 m Urine protein to creatinine ratio g/g creatinine Baseline Hb g/dl LDL mg/dl
25 Mean Hemoglobin (g/dl) Hemoglobin Levels Darbepoetin alfa Placebo Hb Median: 12.5 IQR [ ] Median dose: 176 μg IQR [ ] Mean: 225 μg ± Hb Median: 10.6 IQR [ ] Median dose: 0 μg IQR [0 5] Mean: 5 μg ± Month No. of Patients Darbepoetin alfa Placebo
26 Primary Composite and Component Endpoints Endpoint Darbepoetin alfa N = 2012 Placebo N = 2026 HR (95% CI) P- value CV Composite 632 (31.4) 602 (29.7) 1.05 ( ) 0.41 Death 412 (20.5) 395 (19.5) 1.05 ( ) 0.48 Heart Failure 205 (10.2) 229 (11.3) 0.89 ( ) 0.24 MI 124 (6.2) 129 (6.4) 0.96 ( ) 0.73 Stroke 101 (5.0) 53 (2.6) 1.92 ( ) <0.001 Myocardial Ischaemia 41 (2.0) 49 (2.4) 0.84 ( ) 0.40 Renal Composite 652 (32.4) 618 (30.5) 1.06 ( ) 0.29 ESRD 338 (16.8) 330 (16.3) 1.02 ( ) 0.83
27 Conclusions In patients with Type 2 DM, CKD and anaemia a strategy to treat anaemia with darbepoetin alfa: 1 : Did not reduce either primary composite endpoint of: Death and CV events or Death and ESRD Reduced RBC transfusion FACT-Fatigue modestly improved Higher stroke rates were documented Supports data from cancer studies of higher mortality For many, these risks will outweigh the rather modest potential benefits NEJM 2009
28 TREAT Selected subgroup preliminary analyses History of HF LVEF
29 Heart Failure in TREAT. Preliminary subgroup analysis Hx of HF N = 1347 No Hx of HF N = 2691 Placebo Darb HR Placebo Darb HR /100 patient-years /100 patient-years CV primary Death Fatal & nonfatal HF Stroke * * Preliminary, unpublished data. ESC 2010
30 Heart Failure in TREAT. Patients with baseline LVEF (n = 667, Median EF 52%) All with Hx of HF EF <40% N = 170 EF>40% N = 497 Placebo Darb HR Placebo Darb HR /100 patient-years /100 patient-years CV primary Death Fatal & nonfatal HF Death or HF Stroke * * Preliminary, unpublished data. ESC 2010
31 ESA use in Anemic Heart Failure Patients: Impact on Overall Mortality 9 Randomized, Placebo-controlled Trials of ESA treatment in patients with HF and anemia (n=2039) Study Risk ratio (95% CI) % Weight Mancini (2003) 1.69 (0.08,37.26) 0.3 Cleland (2005) 0.12 (0.01,2.67) 1.0 Ponikowski (2007) 1.16 (0.08,17.28) 0.4 Van Veldhuisen (2007) 6.56 (0.38,114.34) 0.3 Ghali (2008) 0.59 (0.29,1.21) 8.0 Parissis (2008) 0.11 (0.01,2.09) 1.4 Palazzuoli (2009) 0.62 (0.11,3.45) 1.4 Parissis (2009) 0.20 (0.01,3.85) 1.1 TREAT (2009) 1.10 (0.93,1.29) 86.2 (CKD + DM) Overall (95% CI) 1.03 (0.89,1.21) P= Risk ratio χ 2 for Heterogeneity = 10.11, p=0.26 Desai AS, et al. Eur J Heart Fail 2010
32 RED-HF Trial 2600 patients planned primary endpoint: morbidity and mortality target: 620 sites, 32 countries first patients in: July 2006 August 2010: ~ 2/3 of target enrolled
33 Anemia is a readily identifiable surrogate associated with high rates of adverse clinical outcomes. Because ESP can raise hematocrit, it is imperative to definitively determine the risk: benefit ratios of these available therapies. To accept a benefit based on the existing data may be exposing patients to an expensive therapy that is either ineffective or may even contribute to adverse outcome. On the other hand, to accept harm based on existing data may deny patients the ability to improve their prognosis as well as quality of life. Rev Cardiovasc Med 2005
34 I was hoping I d be in the active therapy group! Well, I was hoping I d be in the placebo group! The definition of uncertainty
35
Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationNew horizons in HF: potential of new drugs
New horizons in HF: potential of new drugs Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital Boston, Massachusetts FINANCIAL
More informationAnaemia in Chronic Heart Failure
Anaemia in Chronic Heart Failure 2011 Update Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland DECLARATION OF CONFLICT OF INTEREST
More informationAnemia Update. Target Hb TREAT study Functional iron deficiency - Hepcidin Biosimilar epoetins
Anemia Update Peter Bárány Department of Renal Medicine/ Karolinska University Hospital and Division of Renal Medicine Department of Clinical Science, Intervention and Technology Karolinska Institutet,
More informationSURPRISING FINDINGS FROM CLINICAL TRIALS
IRIM 2012 Brigham and Women s Hospital SURPRISING FINDINGS FROM CLINICAL TRIALS Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationHF-PEF: Symptoms, quality of life and mortality/morbidity
HF-PEF: Symptoms, quality of life and mortality/morbidity May 21, 2011 John McMurray, MD Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham & Women s Hospital Boston; Visiting Professor of Medicine,
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationThe use of surrogates as key performance indicators
REPLY The use of surrogates as key performance indicators Dr José Vinhas Department of Nephrology, Centro Hospitalar de Setúbal. Setúbal, Portugal Received for publication: 24/08/2012 Accepted: 31/08/2012
More informationCurrent Controversies in Anemia: Target Hemoglobin levels and Outcomes Robert Toto, MD
Current Controversies in Anemia: Target Hemoglobin levels and Outcomes Robert Toto, MD Director of Patient-Oriented Research in Nephrology Mary M Conroy Professor of Kidney Diseases Department of Medicine
More informationPeer Review Report. [erythropoietin-stimulating agents]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [erythropoietin-stimulating agents] (1) Does the application adequately address the issue of the public health need
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationEffect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)
Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet Georg Ertl, Michel Komajda,
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationModerators: Heather A. Nyman, Pharm.D., BCPS Clinical Pharmacist, Dialysis, University of Utah Dialysis Program, Salt Lake City, Utah
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P (Knowledge-Based Activity) Monday, October 17 1:30
More informationΔιαχείριση ασθενούς με καρδιακή ανεπάρκεια και αναιμία. Βασιλική Μπιστόλα Καρδιολόγος Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο Αττικό
Διαχείριση ασθενούς με καρδιακή ανεπάρκεια και αναιμία Βασιλική Μπιστόλα Καρδιολόγος Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο Αττικό Based on WHO Definition, 9% of Adults Have Anemia: ARIC Study*
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE
ERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE WEIQIANG GAO HEM/ONC FELLOW FACULTY DISCUSSANT SIOBAN KEEL, MD OCT. 24, 2014 CASE PRESENTATION 25 F, a Jehovah s witness, w/ h/o synovial sarcoma
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationImmunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P Monday, October 17 1:30 p.m. 3:30 p.m. Convention
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationClinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia
Clinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia 8 th November 2004 A report for the National Institute for Clinical Excellence prepared by Amgen Ltd. EXECUTIVE SUMMARY
More informationCitation for published version (APA): Kleijn, L. (2014). Anemia and erythropoietin in cardiovascular disease Groningen: s.n.
University of Groningen Anemia and erythropoietin in cardiovascular disease Kleijn, Lennaert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationFREQUENCY OF ANEMIA AND CLINICAL OUTCOME IN PATIENTS WITH CONGESTIVE HEART FAILURE. Malik Faisal Iftekhar, Abdul Sami,Imran Khan, Akhter Sher
Pak Heart J ORIGINAL ARTICLE FREQUENCY OF ANEMIA AND CLINICAL OUTCOME IN PATIENTS WITH CONGESTIVE HEART FAILURE 1 2 3 4 Malik Faisal Iftekhar, Abdul Sami,Imran Khan, Akhter Sher 1-4 Hayatabad Medical Complex,
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationTreatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
More informationARANESP (darbepoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP (darbepoetin
More informationAnemia and Iron Deficiency: What Every Cardiologist Needs to Know
6th Saudi HF Group Symposium Riyadh - December 8-9, 2017 Anemia and Iron Deficiency: What Every Cardiologist Needs to Know Ammar Chaudhary MBChB, FRCPC Consultant Cardiologist Advanced Heart Failure Department
More informationABSTRACT. n engl j med 361;21 nejm.org november 19,
The new england journal of medicine established in 1812 november 19, 2009 vol. 361 no. 21 A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease Marc A. Pfeffer, M.D., Ph.D., Emmanuel
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationHeart Failure in Women
Heart Failure in Women Disclosure Professor Sindone has received honoraria, speaker fees, consultancy fees, is a member of advisory boards or has appeared on expert panels for: Professor Andrew Sindone
More informationIron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD
Iron Deficiency: New Therapeutic Target in Heart Failure Stefan D. Anker, MD PhD Department of Cardiology, Applied Cachexia Research, Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Germany.
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationEPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas
EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas Disclosure of Interests AstraZeneca (scientific advisory board) Bayer
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationTreatment of Anemia with Dar be po e tin Alfa in Systolic Heart Failure
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Treatment of Anemia with Dar be po e tin Alfa in Systolic Heart Failure Karl Swedberg, M.D., Ph.D., James B. Young, M.D., Inder S.
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationIschemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland
Ischemic and bleeding risk stratification in NSTE ACS Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland Disclosure Andrzej Budaj, MD, PhD, reports the following potential conflicts
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationEfficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis
Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationTransfusion triggers in acute coronary syndromes: The MINT trial
Transfusion triggers in acute coronary syndromes: The MINT trial Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal Objectives Review evidence on transfusion triggers
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil
More informationRegulatory Hurdles for Drug Approvals
Regulatory Hurdles for Drug Approvals William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research 25 min Conflicts CPC Clinical Research
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationThe Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationCAN WE PREDICT THE RISK FOR ADVERSE EVENTS? Andrzej Wiecek, Katowice, Poland
CAN WE PREDICT THE RISK FOR ADVERSE EVENTS? Andrzej Wiecek, Katowice, Poland Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Andrzej Więcek Departm ent of Nephrology,
More informationEffect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial
Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Aldo P. Maggioni, MD, FESC Associazione Nazionale Medici
More informationPRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationIron deficiency in heart failure
Iron deficiency in heart failure Piotr Ponikowski, MD, PhD, FESC Department of Heart Diseases, Wroclaw Medical University Centre for Heart Diseases, Military Hospital, Wroclaw, Poland Objectives Importance
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Probing prognosis in heart failure Daniel R. Wagner CHL/INCCI/CRP-Santé Luxembourg Disclosures Grants: Cordis, Boston Scientific, Medtronic, Sorin, Hexacath, Abbott,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationUniversity of Groningen
University of Groningen Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients Ngo, Katherine; Kotecha, Dipak; Walters, Julia A. E.; Manzano, Luis; Palazzuoli, Alberto; van Veldhuisen,
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More information